Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial

BACKGROUND: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Exp Nephrol
Asıl Yazarlar: Kato, Sawako, Maruyama, Shoichi, Makino, Hirofumi, Wada, Jun, Ogawa, Daisuke, Uzu, Takashi, Araki, Hisazumi, Koya, Daisuke, Kanasaki, Keizo, Oiso, Yutaka, Goto, Motomitsu, Nishiyama, Akira, Kobori, Hiroyuki, Imai, Enyu, Ando, Masahiko, Matsuo, Seiichi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4577308/
https://ncbi.nlm.nih.gov/pubmed/25795029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-015-1106-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller